In the era of targeted therapy for cancer, translational research identifying molecular targets in melanoma offers novel opportunities for potential new treatments.
I n the era of targeted therapy for cancer, translational research identifying molecular targets in melanoma offers novel opportunities for potential new treatments. There is increasing evidence at the molecular level that melanoma is composed of distinct mutational subsets, 1 each harboring different potential targets for therapy. 2 Fresh or frozen tissue is required for the performance of cellular studies (including tissue cultures from primary tumors) and molecular studies (including genomics and proteomics) and for the design and production of biologic treatments. The aforementioned studies cannot be adequately conducted on formalin-fixed, paraffinembedded samples. 3, 4 Needless to say, the development of fresh-frozen tissue banks procured from primary melanomas will likely lead to heightened translational research and may greatly influence diagnosis, prognosis, and therapeutic strategies in the coming years. Histopathological study of formalin-fixed, paraffinembedded specimens is crucial for the diagnosis and staging of melanoma. 4, 5 The risk in randomly procuring samples from freshly excised melanoma specimens for biobanking is that the remaining specimen, which is submitted for formalin-fixed, paraffin-embedded examination, could sustain damage that would preclude adequate histopathological processing. In addition, the random removal of tissue may compromise the ability of the pathologist to evaluate and adequately diagnose the remaining specimen on routine histopathological examination, with untoward clinical and medicolegal consequences. 6, 7 In a previous study, 8 researchers evaluated a method for the procurement of fresh tissue from excisional specimens of melanocytic nevi based on examination with the naked eye; they concluded that the procurement of fresh tissue for research had no influence on the final diagnosis. A method has been described for the use of ex vivo dermoscopy for gross pathological evaluation in the histopathology laboratory. 9 Subsequently, ex vivo dermoscopy was used in 517 cutaneous biopsy specimens, 10 determining that it provides useful ancillary information for the histopathological diagnosis of melanocytic neoplasms. Indeed, dermoscopy can be useful for guiding tissue sectioning for the histopathological correlates, [11] [12] [13] [14] [15] [16] [17] [18] and certain dermoscopic structures can be used to predict melanoma thickness. 19, 20 Given the added value of dermoscopy for performing gross pathological evaluation of melanocytic neoplasms and for predicting microscopic findings on the histopathological examination, we reasoned that dermoscopy can be used to select areas within excisional specimens that could be safely removed for molecular studies without compromising the histopathological evaluation of the specimen. This idea prompted us to explore the use of dermoscopy as an ancillary method for guiding and precisely documenting the procurement of fresh tissue from primary melanoma excisional specimens for molecular research.
Methods
The protocol of ex vivo dermoscopy-oriented sampling of melanoma (DOS-M) was approved by the institutional review board at the Hospital Clinic, Barcelona, Spain. The study setting was an outpatient clinic specializing in melanoma diagnosis and treatment in a tertiary medical center. Within this framework, inclusion criteria for the study were the following: (1) a lesion for which the most likely diagnosis, based on clinical and dermoscopic criteria, was primary cutaneous melanoma; (2) the clinically measured diameter of the lesion exceeded 5 mm in greatest length and width; and (3) informed consent was given by the patient. Exclusion criteria were the following: (1) a lesion for which it was anticipated that the histopathological evaluation may prove problematic or difficult (eg, dermoscopic criteria suggestive of a spitzoid neoplasm) and (2) patients younger than 18 years.
DOS-M Protocol Overview
The entire protocol described below is also depicted via a series of images from a melanoma (Figure) . Six components of the study protocol include the following:
First, all eligible lesions were evaluated with dermoscopy before surgery (in vivo dermoscopy). Areas of interest for sampling within the lesions were identified.
Second, lesions were surgically excised with narrow margins. These were 2 mm or 5 mm, according to routine practice.
Third, dermoscopy was used on the freshly excised specimen (ex vivo dermoscopy) to identify the previously identified (in vivo) areas of interest for sampling. Tissue samples were incised from within the excisional specimen using a 2-mm to 3-mm punch (Figure) according to the size of the tumor; a 3-mm punch was used when the diameter exceeded 20 mm. Areas anticipated as being the thickest portion of the lesion (see the evaluation of melanoma thickness below under the Study 1 and Study 2 subheadings) were not sampled by incision but were preserved for the assessment of Breslow thickness during the histopathological analysis. For example, if a nodule was identified within the melanoma, only the peripheral part of the nodule was incised for fresh tissue sampling, while the center of the nodule, predicted to be the thickest part, was preserved for the histopathological analysis. Incisional sampling was also not obtained from areas showing dermoscopically equivocal findings that precluded the prediction of thickness.
Fourth, the excisional specimen was submitted for routine pathology laboratory processing. Excised tissue specimens underwent routine formalin fixation and paraffin embedding; vertical sections were stained with hematoxylineosin (H&E). The final histopathological diagnosis was based on the evaluation of slides obtained from step-sectioning of the remaining excisional specimens. All histopathological slides were evaluated by at least 2 pathologists (J.P. and L.A.) and analyzed for mitoses, Clark level, Breslow thickness, neural invasion, lymphatic invasion, type of inflammatory infiltrate, growth phase (radial vs vertical), and the presence of ulceration, regression, and microsatellites.
Fifth, incised tissue samples were embedded in formalin in study 1 (comparison of Breslow thickness between incised samples and the remaining specimen). Alternatively, they were cryopreserved at −80°C for biobanking in study 2 (dermoscopic agreement study).
Sixth, all cases were discussed during a clinicopathological conference (CPC), in the presence of the dermatologists and pathologists (J.P. and L.A.) involved in the study, to determine whether incisional sampling of the melanoma could adversely influence the diagnosis and staging of the melanomas. The frozen samples of the melanomas were not processed for molecular studies until after the participants of the CPC had reached a consensus decision that H&E histopathological analysis of the frozen samples was unlikely to change the diagnosis or staging of the melanoma.
Imaging of Lesions and Documentation of Sampling
We obtained clinical and contact polarized dermoscopic images of all primary melanomas included in the study to precisely document sampling of tissue from within the lesions (Figure) . Images of the melanomas were acquired in the fol- 
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Ex Vivo Dermoscopy for Biobank-Oriented Sampling lowing sequence: (1) before surgical excision (clinical and in vivo dermoscopic images), (2) immediately after surgical excision (ex vivo dermoscopic images), and (3) after obtaining incisional punch samples from within the excised melanoma specimen (ex vivo dermoscopic images). All ex vivo images were acquired before formalin fixation of specimens. Images were obtained with a camera (PowerShot G7; Canon Inc or CoolPix 4500; Nikon Inc). All in vivo dermoscopic images were captured using the same cameras attached to a polarized contact dermoscopic lens (DermLite Foto; 3GEN, LLC). During ex vivo contact dermoscopic photography, the excised specimen was covered with a sterile plastic wrap (transparent wrap used for instrumental or dressing sterilization) to avoid contamination of the lens. As described by Zampino and coworkers, 21, 22 we affirm that obtaining the dermoscopic images through a plastic wrap does not alter image quality. In addition to the clinical and dermoscopic images, a schematic drawing of the lesion was generated before formalin fixation ( Figure) to annotate the sites of tissue sampling within the excised melanoma specimen. Annotation included a description of the clinical findings (colors, ulceration, and mapping of flat areas or papules or nodules) and the dermoscopic features (specifically, ulceration, blue-white veil, and atypical vessels).
All clinical and dermoscopic images and schematic drawings were sent to the pathology laboratory together with the formalin-fixed specimens. Special attention was given to the identification and annotation of areas within the melanoma that were predicted to have the greatest Breslow thickness in the histopathological analysis; these areas were clearly marked in the in vivo dermoscopic image and in the schematic drawing of the melanoma to guide the gross pathological examination in the pathology laboratory ( Figure) .
Study 1 (Comparison of Breslow Thickness Between Incised Samples and the Remaining Specimen)
As a proof of principle, study 1 tested the notion that the thickest portion of the melanoma can be preserved for the histopathological examination based on gross (clinical and dermoscopic) assessment before the procurement. In a subset of 10 melanomas, the incisional punch samples were not cryopreserved for biobanking but rather were submitted for routine histopathological analysis with the remaining excisional specimen. The Breslow thickness of the incisional punch samples was compared with the maximal Breslow thickness measurement of the remaining excisional specimen.
Study 2 (Dermoscopic Agreement Study)
Study 2 determined agreement between 2 independent observers on dermoscopic identification of the thickest part of the melanoma. This study was performed on 43 additional melanomas.
Agreement on Dermoscopic Identification of the Thickest Portion of the Melanoma
The prediction of the thickest portion was based on gross evaluation (clinical and dermoscopic) of the melanoma using criteria previously defined by Argenziano et al. 19 According to this method, the thickest parts of the melanoma correlate clinically and dermoscopically. Clinically, the thickest parts correlate with (1) nodular parts of the tumor and (2) areas of ulceration. Dermoscopically, the thickest parts correlate with (1) gray-blue areas, also known as bluewhite veil, that correspond to irregular, confluent, gray-blue diffuse pigmentation present focally within the lesion (ie, does not occupy the entire surface area of the lesion) and (2) areas showing an atypical vascular pattern, particularly in hypomelanotic melanomas.
To test the reproducibility of the prediction of the thickest portion of melanoma, an interobserver agreement study was performed. Specifically, in vivo and ex vivo images of 43 melanomas were mapped using a digital grid constructed for the study, which divided the melanoma into numbered blocks. These images were evaluated by 2 independent observers (G.S. and L.L.), who were asked to select the block most likely to contain the thickest part of the melanoma.
Concordance of Dermoscopic Features Between In Vivo and Ex Vivo Images
Implementation of the DOS-M protocol is contingent on good bedside (in vivo) to bench (ex vivo) concordance on the identification of the morphological attributes of the melanoma. To test this concordance, we performed an interobserver agreement study between dermoscopic features identified in vivo and ex vivo. The 2 sets of dermoscopic images were separately analyzed for global dermoscopic pattern, the distribution of dermoscopic structures (asymmetry), the presence of colors (light brown, dark brown, black, blue-gray, white, pink, and red), and the presence of dermoscopic structures (bluewhite veil, atypical vessels, regression structures, atypical pigment network, atypical dots and globules, streaks or atypical streaks, and blotches or atypical blotches).
Statistical Analysis
Descriptive statistics were used to characterize the histopathological attributes of included melanomas. To compare the findings of in vivo and ex vivo dermoscopy in study 2, correlation statistics (Spearman rank correlation coefficient and Pearson product moment correlation R and κ) were calculated. A κ statistic exceeding 0.8 denotes excellent correlation, while a κ statistic of less than 0.2 is considered poor correlation.
Results

Study 1 (Comparison of Breslow Thickness Between Incised Samples and the Remaining Specimen)
Ten consecutive melanomas, diagnosed at the melanoma clinic, were included in study 1 and processed using the DOS-M procedure of dermoscopy-guided tissue sampling ( Table 1) . The study set comprised 9 invasive melanomas with a mean Breslow thickness of 2.25 mm (range, 0.55-6.00 mm) and 1 in situ melanoma. Of 9 invasive melanomas, 7 were superficial spreading, 1 was acral lentiginous, and 1 was a desmoplastic melanoma arising in a lentigo maligna melanoma. Histopathologically identified ulceration was present in 2 of the melanomas. Two blinded pathologists evaluated both parts of each tu-mor. The maximal Breslow thickness was measured and compared between the incised sample and the remaining main tissue specimen for each of 10 melanomas. In all 10 melanomas, the area of maximal Breslow thickness was not sampled and remained in the main tumor specimen.
Study 2 (Dermoscopic Agreement Study)
Forty-three consecutive melanomas were prospectively included in study 2 and processed using the DOS-M procedure ( Table 2 ). The mean clinical diameter of the melanomas (in the smaller dimension) was 16.5 mm (range, 6.0-41.0 mm). In the histopathological analysis, the study set comprised 35 invasive melanomas (81%) with a mean Breslow thickness of 1.49 mm (median, 1.10 mm; range, 0.40-5.40 mm) and 8 in situ melanomas (19%). Histopathologically identified ulceration was present in 4 of 43 melanomas (9%). Of 35 invasive melanomas, 29 (83%) were classified as superficial spreading melanoma, 4 (11%) as nodular melanoma, 1 (3%) as acral lentiginous melanoma, and 1 (3%) as lentigo maligna melanoma.
Agreement on Dermoscopic Identification of the Thickest Portion of the Melanoma
Two independent observers (G.S. and L.L.) retrospectively analyzed the dermoscopic images from each melanoma and selected the sector on the study grid most likely to contain the thickest part of the melanoma. Concordance was 93% on the selection of the sector likely to be the thickest.
Concordance of Dermoscopic Features Between In Vivo and Ex Vivo Images
Dermoscopic attributes were compared between in vivo and ex vivo images of the melanomas ( Table 3) . There was excellent agreement (κ > 0.8) on the categorization of global dermoscopic pattern, the distribution of dermoscopic structures (asymmetry), the presence of colors (light brown, dark brown, black, blue-gray, and white), and the presence of dermoscopic structures (streaks, blue-white veil, regression structures, atypical dots and globules, atypical pigment network, and blotches or atypical blotches). Poor correlation (κ < 0.2) was observed for the presence of atypical vessels and the finding of pink or red; blood vessels and vascular blush were not observable under ex vivo dermoscopy.
CPC on Sampled Melanomas
All 43 melanomas included in study 2 were jointly analyzed at a CPC to determine whether incisional sampling of the melanoma could adversely influence the diagnosis and staging of the melanomas. Although all frozen incisional samples were readily available from the tissue bank and, if needed, could have been subjected to H&E histopathological assessment, the consensus opinion by participating pathologists and dermatologists was that this was unlikely to change the diagnosis and final staging for any of the melanomas included in study 2.
Discussion
This study introduces the use of dermoscopy for guiding tissue sampling. Dermoscopy can serve as a bridge between clinicians and pathologists because it provides a gross pathological map of the melanoma, available both at the bedside (in vivo) and pathology bench (ex vivo). 10 Indeed, the findings reported herein suggest that dermoscopic evaluation and imaging of tissue can be performed ex vivo, with proficiency comparable to that of in vivo dermoscopy, and that the dermoscopic images can be used to create a tumor map, which in turn can serve as a guide for fresh tissue sampling. In addition, the present study supports prior observation that dermoscopic criteria for tumor thickness can be applied in a reproducible manner. 18 High concordance was shown between 2 independent observers in the clinical and dermoscopic identification of the thickest area of the melanomas. Furthermore, the area with maximal Breslow thickness of the melanoma was shown to be retained within the excised melanoma specimen under the DOS-M technique. Indeed, in a subset of 10 melanomas, the incised samples were submitted for routine H&E histopathological analysis (rather than being diverted to biobanking) and were shown to be thinner in Breslow thickness than the remaining main excisional specimen. Experience in dermoscopy is required to perform gross thick- ness evaluation to minimize the risk that sampling will remove portions of the melanoma that are important for the final diagnosis and staging. For the DOS-M protocol described herein, it is important to precisely document areas sampled by annotating the dermoscopic images and schematics ( Figure) ; these documents should be included in the report sent to the tissue bank registry and to the pathology laboratory registry. This allows clinicians and pathologists to know exactly which parts of the melanoma were sampled and which parts of the melanoma were available for routine H&E processing. The prepathological sampling of the lesion using the DOS-M method should be reflected in the pathology report. The successful implementation of the DOS-M protocol is contingent on having an interactive and collegial multidisciplinary research team composed of dermatologists, surgeons, pathologists, and biologists. In the present study, while the cryopreserved procured tissues were available for H&E histopathological analysis, our pathologists did not deem it necessary to use them in rendering a final histopathological diagnosis. They reasoned that dermoscopy-guided sampling and availability of precise documentation of the gross pathological examination probably lead to comparable, if not better, sampling of melanoma compared with routine, blinded, mostly random tissue gross pathological examination.
At present, this procedure should be restricted to experienced research centers with a well-defined protocol that will ensure the precise diagnosis and staging of patients. Nevertheless, highly specialized skin pathology providers might embrace similar protocols in the future.
In applying the DOS-M protocol, we note the following 5 points: (1) Samples should only be obtained from areas that will not interfere with the pathologist's ability to render a definitive diagnosis and to provide accurate prognostic information. (2) Sampling should not be obtained from tumors for which one suspects that the histopathological evaluation may prove difficult or for which the evaluation of the entire tumor would be crucial (eg, dermoscopically equivocal lesions, melanoma arising in a nevus, and lesions with extensive regres- sion). (3) Sampling should not be performed on small melanomas; we recommend a minimum diameter of 10 mm because sampling from larger melanomas leaves behind sufficient tissue for the histopathological evaluation. (4) A CPC should be held regularly to review the cases together with the clinical images, in vivo and ex vivo dermoscopy images, and the annotated maps. (5) The procured frozen biobank tissue samples for molecular analyses should be made available for routine H&E histopathological evaluation until the final pathology report is produced if deemed necessary by CPC consensus. Our study has limitations. First, the single-study includes few cases. Second, the determination of Breslow thickness among incisional samples was only performed for a subset of the melanomas. Third, only lesions recognized clinically and dermoscopically as likely melanomas were included. If molecular studies are to be used for the differentiation of melanoma from benign lesions, sampling should probably also include cases with an equivocal diagnosis.
In conclusion, we have developed a technique for dermoscopy-guided sampling of small portions of any given melanoma. This technique is the first step in sampling melanomas for the purpose of biobanking freshly excised tissue for molecular studies. Dermoscopy can be applied ex vivo to freshly excised tissues, with the findings comparable to those of in vivo examination. The thickest portion of the melanoma can be reproducibly identified and documented under the DOS-M protocol, allowing incisional sampling of areas within the melanoma that would not compromise the final histopathological diagnosis and staging. Finally, it is fundamental to restrict this DOS-M procedure to medical centers with an interdisciplinary team composed of clinicians with expertise in dermoscopic evaluation of melanoma and of dermatopathologists with expertise in the evaluation of melanocytic neoplasms. In our experience, such a strategy translates to better communication among dermatopathologists, clinicians, and researchers. She and her husband, John Adams, were at the heart of the American Revolution. While John Adams served as a Massachusetts delegate to the Continental Congress, Abigail Adams melted down her treasured pewter spoons to make bullets for Minutemen troops. 1 As advisor to her husband, Abigail Adams helped formulate the arguments he used to sway the Continental Congress to adopt the Declaration of Independence on July 2, 1776. Americans faced another terrible enemy besides British forces: smallpox. During 1776, a deadly epidemic of smallpox gripped the Boston area. Alarmed, the Massachusetts legislature, on July 3, 1776, lifted a ban on variolation, a controversial, risky procedure in which people were inoculated with variola virus taken from skin lesions of smallpox victims. Variolation usually caused a milder, potentially less fatal case of smallpox than did naturally acquired infection and produced immunity.
To protect her children from smallpox, Abigail Adams bravely took her family from Braintree, Massachusetts, to Boston to be inoculated. The physician who performed the inoculation was Dr Thomas Bullfinch, an expert in the Suttonian method of variolation. 2 Developed in England, this technique sought to reduce the risks of variolation in several ways: (1) by minimizing lengthy preprocedure emetic regimens, (2) by using a superficial skin incision rather than a deep cut, and (3) through a careful selection of infected material obtained from the skin lesions of inoculated persons rather than from patients with natural smallpox. 3 During the 19th century, variolation was replaced by Jennerian vaccination.
On July 12, 1776, Abigail Adams and her 4 children were inoculated in the arm. Abigail Adams and John Quincy, age 9 years and the future sixth American President, had mild skin reactions. Daughter Nabby, age 11 years, developed an extensive smallpox eruption. Charles, age 6 years, and Thomas, age 4 years, required reinoculation having failed to develop any skin reaction. Thomas subsequently had a mild skin reaction, but Charles developed a more extensive eruption. Everyone recovered from the procedure.
On July 18, 1776, Abigail Adams attended, with much pride, the public reading of the Declaration of Independence in Boston. John and Abigail Adams would later serve our country as its second President and First Lady.
The Declaration of Independence was written and signed by men. Yet, this great document also embodies the spirit of many courageous women, such as Abigail Adams, who shared with their husbands the dreams of liberty and the struggle for American freedom. Despite epidemics of disease and hardships of war, these women stood firm in their resolve to give birth to a new nation in which all Americans would enjoy the blessings of life, liberty, and the pursuit of happiness.
